Based on this study, trimetrexate provides an effective and well- tolerated therapy for patients who are intolerant of or refractory to TMP-SMX, and will greatly add to the therapeutic armamentarium of drugs to treat PCP," Dr.
Trimetrexate belongs to a class of compounds known as antifolates.
In this study, trimetrexate was given intravenously at 45 mg/M2 once daily with intravenous leucovorin at 20 mg/M2 at every six hours.
The patients receiving study therapy outside of the hospital were given trimetrexate once daily by intravenous infusion and administered leucovorin orally.
The once-daily IV infusion with trimetrexate was convenient and effective and posed little obstacle for patients transitioning to IV therapy in an ambulatory setting," Dr.
Trimetrexate is administered as a once-daily IV therapy with oral leucovorin provided four times daily, making it convenient to administer, control and monitor.
He concluded, "Until such combination therapies involving trimetrexate are thoroughly studied, trimetrexate plus leucovorin without a dihydropteroate synthetase inhibitor will provide a useful treatment to be added to the limited number of drugs that can be given intravenously for moderate-to-severe PCP in patients who are not candidates for TMP-SMX.